KAT2A 通过促进 PKM2 的琥珀酰化来抑制其活性并加速胃癌的糖酵解。
KAT2A Promotes the Succinylation of PKM2 to Inhibit its Activity and Accelerate Glycolysis of Gastric Cancer.
机构信息
Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Department of General Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
出版信息
Mol Biotechnol. 2024 Jun;66(6):1446-1457. doi: 10.1007/s12033-023-00778-z. Epub 2023 Jun 9.
Gastric cancer (GC) is one of the main causes of cancer-related death. Lysine acetyltransferases 2 A (KAT2A) is a succinyltransferase that plays an essential role in cancer development. The pyruvate kinase M2 (PKM2) is a glycolysis rate-limiting enzyme that mediates the glycolysis of cancers. This study aimed to explore the effects and mechanism of KAT2A in GC progression. The effects of biological behaviors of GC cells were evaluated by MTT, colony formation and seahorse assays. The succinylation modification was assessed by immunoprecipitation (IP). The interaction between proteins were detected by Co-IP and immunofluorescence. A pyruvate kinase activity detection kit was used to evaluate the activity of PKM2. Western blot was performed to detect the expression and oligomerization of protein. Herein, we confirmed that KAT2A was highly expressed in GC tissues and was associated with a poor prognosis. Function studies showed that knockdown of KAT2A inhibited cell proliferation and glycolytic metabolism of GC. Mechanistically, KAT2A could directly interacted with PKM2 and KAT2A silencing inhibited the succinylation of PKM2 at K475 site. In addition, the succinylation of PKM2 altered its activity rather than its protein levels. Rescue experiments showed that KAT2A promoted GC cell growth, glycolysis, and tumor growth by promoting PKM2 K475 succinylation. Taken together, KAT2A promotes the succinylation of PKM2 at K475 to inhibit PKM2 activity, thus promotes the progression of GC. Therefore, targeting KATA2 and PKM2 may provide novel strategies for the treatment of GC.
胃癌(GC)是癌症相关死亡的主要原因之一。赖氨酸乙酰转移酶 2A(KAT2A)是一种琥珀酰基转移酶,在癌症发展中起着至关重要的作用。丙酮酸激酶 M2(PKM2)是一种糖酵解限速酶,介导癌症的糖酵解。本研究旨在探讨 KAT2A 在 GC 进展中的作用和机制。通过 MTT、集落形成和 Seahorse 测定评估 GC 细胞生物学行为的影响。通过免疫沉淀(IP)评估琥珀酰化修饰。通过 Co-IP 和免疫荧光检测蛋白质之间的相互作用。使用丙酮酸激酶活性检测试剂盒评估 PKM2 的活性。通过 Western blot 检测蛋白的表达和寡聚化。在此,我们证实 KAT2A 在 GC 组织中高度表达,并与预后不良相关。功能研究表明,敲低 KAT2A 抑制 GC 细胞的增殖和糖酵解代谢。在机制上,KAT2A 可以直接与 PKM2 相互作用,KAT2A 沉默抑制 PKM2 在 K475 位的琥珀酰化。此外,PKM2 的琥珀酰化改变了其活性而不是其蛋白水平。挽救实验表明,KAT2A 通过促进 PKM2 K475 琥珀酰化来促进 GC 细胞生长、糖酵解和肿瘤生长。综上所述,KAT2A 促进 PKM2 在 K475 位的琥珀酰化,抑制 PKM2 活性,从而促进 GC 的进展。因此,靶向 KATA2 和 PKM2 可能为 GC 的治疗提供新的策略。